The results indicated that treatment with the SCG2 protein dramatically inhibited SW620 tumor growth as compared with the controls (IgG) by 64.7% in tumor volume (419.6 ± 91.0 vs. 1190.2 ± 163.7 mm3, respectively, Fig. 7B,C) and by 64.3% in tumor weight (0.38 ± 0.05 vs. 1.08 ± 0.12 g, respectively, Fig. 7D). This evidence concerns the gene SCG2 and neoplasm.